Vaccine Current Affairs - 2020
On April 3, 2020, the Government of India launched 5 research projects in order to control the spread of COVID-19. The projects neither focus on vaccines nor on medicines. GoI has been very clear and has also announced earlier that it is currently not into developing medicine for COVID-19. Rather the first priority is to mitigate the spread. The research projects were selected based on this plan.
The projects are to be supervised by the Department of Science and Technology
The first project aims to search the metabolite biomarker signature for the virus. These markers will help in capturing the activities of the cell or an organism infected with the virus. This knowledge is base for developing potential drug for the vaccines
The second project is to develop viricidal coatings that shall be used in surgical masks to prevent the spread of highly contagious viruses such as SARS, COVID-19, etc.
The third project is to develop antiviral surface coatings to help prevent the spread of infections caused by influenza virus. The aim is to develop polymeric compounds that will be coated upon surfaces and will kill the viruses completely upon contact.
The fourth project is to develop a material which when applied over surfaces will remove viruses and bacteria adhering to it.
The fifth project is to develop antibody-based capture of COVID-19 and inactivate it using lipid based gel.
Intensification of Research in High Priority Areas Scheme
The projects have been launched under IRPHA scheme. The scheme is implemented by SERB, Science and Engineering Research Board. SERB operated under Department of Science and Technology. Apart from these 5 projects small projects like data driven approach to contain the spread of the virus is also being launched.
Tags: Bacteria • Bio engineering • Biotechnology • Corona Virus • COVID-19
Bharat Biotech along with virologists of University of Wisconsin and Madison have begun development and testing of a new vaccine called CoroFlu for COVID-19.
The vaccine is to be developed with the M2SR vaccine as the main component. The M2SR vaccine is used against flu. The M2SR is a self-limiting version of the influenza virus. It induces immune response against flu.
The gene sequences of SARS-CoV-2 that causes the COVID-19 disease is to be inserted into the M2SR. This will induce immunity against corona virus. The process is expected to take three to six months. The vaccine will be delivered intranasally.
The Bharat Biotech is to manufacture around 300 million doses of the vaccine. The doses are to be distributed all over the world.
Bharat Biotech is an Indian Biotechnology company. It is headquartered at Hyderabad. It was founded by Krishna Ella, an Indian Scientist. It is the first bio-pharma company audited and approved by the Korean Food and Drugs Administration, Hyderabad.
Tags: Biotechnology • Corona Virus • COVID-19 • Department of Biotechnology (DBT) • Drugs